El valor de la selección de pacientes en NSCLC: tratamiento de segunda línea en pacientes PD-L1 positivo - page 35

Targeted therapy

Immune checkpoint therapy

Chemotherapy

Hypothetical KM curve

Time

Percent survival

Gran Beneficio

Moderado

Beneficio

Escaso

Beneficio

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,25,26,27,28,29,30,31,32,33,34 36,37,38,39,40,41,42,43